196 related articles for article (PubMed ID: 27034432)
1. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
4. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
[TBL] [Abstract][Full Text] [Related]
5. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Maxson JE; Ries RE; Wang YC; Gerbing RB; Kolb EA; Thompson SL; Guidry Auvil JM; Marra MA; Ma Y; Zong Z; Mungall AJ; Moore R; Long W; Gesuwan P; Davidsen TM; Hermida LC; Hughes SB; Farrar JE; Radich JP; Smith MA; Gerhard DS; Gamis AS; Alonzo TA; Meshinchi S
Blood; 2016 Jun; 127(24):3094-8. PubMed ID: 27143256
[No Abstract] [Full Text] [Related]
6. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
Braun TP; Okhovat M; Coblentz C; Carratt SA; Foley A; Schonrock Z; Curtiss BM; Nevonen K; Davis B; Garcia B; LaTocha D; Weeder BR; Grzadkowski MR; Estabrook JC; Manning HG; Watanabe-Smith K; Jeng S; Smith JL; Leonti AR; Ries RE; McWeeney S; Di Genua C; Drissen R; Nerlov C; Meshinchi S; Carbone L; Druker BJ; Maxson JE
Nat Commun; 2019 Nov; 10(1):5455. PubMed ID: 31784538
[TBL] [Abstract][Full Text] [Related]
7. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
[TBL] [Abstract][Full Text] [Related]
8. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
9. [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].
Su L; Tan YH; Lin H; Han W; Yang YP; Liu XL; Sun JN; Liu QJ; Gao SJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1021-1027. PubMed ID: 36709108
[No Abstract] [Full Text] [Related]
10. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
11. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
Wilhelmson AS; Porse BT
Br J Haematol; 2020 Aug; 190(4):495-507. PubMed ID: 32086816
[TBL] [Abstract][Full Text] [Related]
12. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
Wang B; Wen L; Wang Z; Chen S; Qiu H
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Sensitive
Klimiankou M; Uenalan M; Kandabarau S; Nustede R; Steiert I; Mellor-Heineke S; Zeidler C; Skokowa J; Welte K
Front Immunol; 2019; 10():116. PubMed ID: 30891028
[TBL] [Abstract][Full Text] [Related]
16. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
17. Genetic heterogeneity of cytogenetically normal AML with mutations of
Konstandin NP; Pastore F; Herold T; Dufour A; Rothenberg-Thurley M; Hinrichsen T; Ksienzyk B; Tschuri S; Schneider S; Hoster E; Berdel WE; Woermann BJ; Sauerland MC; Braess J; Bohlander SK; Klein HG; Hiddemann W; Metzeler KH; Spiekermann K
Blood Adv; 2018 Oct; 2(20):2724-2731. PubMed ID: 30337300
[TBL] [Abstract][Full Text] [Related]
18. A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.
Spiciarich DR; Oh ST; Foley A; Hughes SB; Mauro MJ; Abdel-Wahab O; Press RD; Viner R; Thompson SL; Chen Q; Azadi P; Bertozzi CR; Maxson JE
Cancer Res; 2018 Dec; 78(24):6762-6770. PubMed ID: 30348809
[TBL] [Abstract][Full Text] [Related]
19. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.
Figueroa ME; Wouters BJ; Skrabanek L; Glass J; Li Y; Erpelinck-Verschueren CA; Langerak AW; Löwenberg B; Fazzari M; Greally JM; Valk PJ; Melnick A; Delwel R
Blood; 2009 Mar; 113(12):2795-804. PubMed ID: 19168792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]